TSAI Albert

Professor TSAI Albert, Jr.

  • Chief Medical Officer, Zhaoke Ophthalmology Ltd.

Dr. Albert Tsai Jr. was appointed as the CMO of our Group on June 1, 2021. He is primarily responsible for leading the Group to advance its assets through the clinical development process as well as supporting the post-approval medical affairs for the Group’s commercial products (e.g. safety, risk management, thought leader relationships). Dr. Tsai has 20 years of healthcare experience across the spectrum of pharmaceuticals, biotech, medical devices and healthcare consulting, as well as in various country markets including China, U.S., Japan and Southeast Asia. From 2019 to 2021, he served as the vice president, regional medical officer of the Asia-Pacific region at PPD Inc., a leading global contract research organization, responsible for business development and providing medical/scientific product development advisory to biotech companies in Asia. Prior to that, he served as vice president, Asia Pacific at The Medicines Company Hong Kong, a company listed on the NASDAQ (stock code: MDCO) from 2014 to 2019, where he developed and implemented the Asia expansion strategy for The Medicines Company Hong Kong with a primary focus on establishing their presence in China and Japan. From 1997 to 2014, he worked in various leading global pharmaceutical companies including Bayer Schering Pharma AG, Merck Sharp & Dohme (Asia) Ltd., Amgen Inc. and GE Healthcare Inc. in senior medical positions. Dr. Tsai obtained his doctor of medicine from Northwestern University and master of business administration in strategy and finance from University of Southern California.